Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with rare lung disease: long-term drug safety trial completed

NCT ID NCT05285982

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of a medicine called nintedanib in children and teenagers with a rare lung condition that causes scarring (fibrosing interstitial lung disease). All 54 participants took nintedanib capsules twice a day for at least 1.5 to 3 years. The goal was to see how well children tolerate this treatment over time, since it is already used in adults. The study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBROSING INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG DISEASES, INTERSTITIAL

Contacts and locations

Locations

  • Azienda Ospedaliera Meyer

    Florence, 50139, Italy

  • BC Children's Hospital

    Vancouver, British Columbia, V6H 3N1, Canada

  • Brussels - UNIV HUDERF

    Brussels, 1020, Belgium

  • Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP

    São Paulo, 5403-900, Brazil

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15224, United States

  • Clinical Research Institute S.C.

    Tlalnepantla, 54055, Mexico

  • General Hospital of Thessaloniki "Ippokrateio"

    Thessaloniki, 54642, Greece

  • HOP Intercommunal

    Créteil, 94010, France

  • Hamburger Zentrum für Kinder- und Jugendrheumatologie

    Hamburg, 22081, Germany

  • Hospital Universitari Vall D Hebron

    Barcelona, 08035, Spain

  • Hospital Virgen del Rocío

    Seville, 41013, Spain

  • Hospital de Niños Dr. Ricardo Gutierrez

    CABA, C1425EFD, Argentina

  • Hospital de Pediatria Prof. Dr. Juan P. Garrahan

    CABA, C1245AAM, Argentina

  • Independent Public Teaching Children's Hospital

    Warsaw, 02091, Poland

  • King's College Hospital

    London, SE5 9RS, United Kingdom

  • Oslo Universitetssykehus HF, Rikshospitalet

    Oslo, N-0372, Norway

  • Osp. Pediatrico Bambin Gesù

    Roma, 00165, Italy

  • Serviços Medicos Respirar Sul Fluminense

    Barra Mansa, 27323240, Brazil

  • Tampere University Hospital

    Tampere, 33520, Finland

  • Teaching Hospital Motol, Oncology Clinic

    Prague, 150 06, Czechia

  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

  • ULS de Santa Maria, E.P.E

    Lisbon, 1649-035, Portugal

  • ULS de São José, E.P.E. - Hospital Dona Estefânia

    Lisbon, 1169-045, Portugal

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Weill Cornell Medicine-New York-60569

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.